Education. Evidence. Regrowth.
Prioritize knowledge. Make better choices.
Sort good studies from the bad.
Get bigger hair gains.
PhD's, resarchers, & consumer advocates.
Founder, researcher, & consumer advocate
Our team of PhD’s, researchers, & more
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
I have attached my before and afters of my progress since joining this group...
I’m convinced I’ve recovered to probably the hairline I had 3 years ago. Super stoked…
My friends actually told me, “Your hairline improved. Your hair looks thicker...
I also feel my hair has a different texture to it now…
Firstly thank you for your work in this field. I am immensely grateful that...
I just wanted to thank you for all your research, for introducing me to this method...
To be honest I am having fun with all this and I still don’t know how much...
I see a massive amount of regrowth that is all less than about 8 cm long...
150+ member experiences.
Popular treatments. But do they work?
Top-selling ingredients, quantified.
The truth about hair loss "best sellers".
Xyon Health
Strut Health
Happy Head
DS Laboratories
Advanced Trichology
Fully Vital
Xyon Health
DrFormulas
Revivogen MD
Standardized rubrics to evaluate all treatments.
Is this treatment well studied?
How much regrowth can you expect?
Is this treatment safe & sustainable?
Apps, tools, guides, freebies, & more.
100+ free articles.
Our team’s peer-reviewed studies.
Education. Evidence. Regrowth.
PhD's, resarchers, & consumer advocates.
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
Read the experiences of members
Get personalized support, product recommendations, video calls, and more from our researchers, trichologists, and PhD's dedicated to getting you the best possible outcomes.
Learn MoreOral minoxidil, once a blood pressure medication, is now gaining traction as a powerful off-label treatment for hair loss. But how does it compare to topical minoxidil, and is it safe? In this article, we explore the mechanisms behind oral minoxidil’s hair growth effects, its role in treating different types of alopecia, the latest clinical data on safety and efficacy, and practical guidance for minimizing side effects while maximizing results.
Oral minoxidil is an increasingly popular off-label treatment for hair loss, offering a convenient alternative to topical solutions for both men and women. Originally developed as a blood pressure medication, it was discovered to promote hair growth, sometimes dramatically, by enhancing blood flow and stimulating key pathways involved in hair growth.
In this article, we break down what oral minoxidil is, how it works, what the research reveals across different types of hair loss, potential side effects, and best practices for safe and effective use.
Oral minoxidil is a medication originally developed in the 1970s as an oral hypertensive agent, designed to lower high blood pressure by acting as a potent vasodilator. During its use for hypertension, clinicians observed a notable side effect: increased hair growth, or hypertrichosis.[1]Patel, P., Nessel, T.A., Kumar, D. (2023). Minoxidil. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/book/NBK482378/ Accessed: … Continue reading
This unexpected effect led to the development of topical minoxidil for hair loss, which was approved by the FDA in 1988 for male patients and in 1992 for female patients.[2]Nestor, M.S., Ablon, G., Gade, A., Han, H., Fischer, D.L. (2021). Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. Journal of … Continue reading Oral minoxidil is also used as an off-label treatment for both men and women.
Many people consider oral minoxidil over topical due to fundamental differences in how each form is activated and delivered to hair follicles. Topical minoxidil is a pro-drug that requires conversion to its active form, minoxidil sulfate, by the sulfotransferase enzyme (specifically SULT1A1) located in the outer root sheath of scalp hair follicles.[3]Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a … Continue reading
However, the activity of this enzyme varies significantly between individuals. For example, in one study on 120 patients, 40.8% exhibited low levels of sulfotransferase activity in the scalp.[4]Chitalia, J., Dhurat, R., Goren, A., McCoy, J., Kovacevic, M., Situm, M., Naccarato, T., Lotti, T. (2018). Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern … Continue reading
Additionally, topical minoxidil faces a “penetration problem” where only about 1.4% of the drug applied is actually absorbed into the scalp skin under normal conditions.[5]Suchonwanit, P., Thammarucha, S., Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: … Continue reading
Oral minoxidil largely bypasses these limitations. When taken by mouth, minoxidil is absorbed through the gastrointestinal tract and converted to its active form in the liver, where sulfotransferase activity is abundant. This ensures that nearly all ingested minoxidil is activated and delivered systemically, reaching hair follicles throughout the scalp and body, regardless of individual differences in scalp enzyme activity. As a result, oral minoxidil can be effective even for those who are non-responders to topical therapy due to low scalp sulfotransferase activity or poor drug penetration.[6]Beach, R.A. (2018). Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C’s of oral therapy. Dermatologic Therapy. 31(6). E12707. Available at: … Continue reading
Oral minoxidil promotes hair growth through several interrelated mechanisms at the cellular and molecular levels.
Minoxidil is converted in the liver to its active form, minoxidil sulfate (first phase metabolism), which opens adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle and hair follicle cells.[7]Gupta, A.K., Talukder, M., Shemar, A., Priaccini, B.A., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: … Continue reading
This action triggers a process known as membrane hyperpolarization, resulting in vasodilation and increased blood flow to the scalp. This increased microcirculation delivers more oxygen, nutrients, and growth factors to hair follicles, creating a favorable environment for hair growth.
Minoxidil shortens the telogen (resting) phase and induces early entry of hair follicles into the anagen (growth) phase.[8]Suchonwanit, P., Thammarucha, S., Leerunyakul, K. (2019). Minoxidil and its use in hair loss disorders. Drug Design, Development and Therapy. 13. 2777-2786. Available at: … Continue reading It also prolongs the duration of anagen, leading to longer and potentially thicker hair.
Minoxidil has been shown to activate the Wnt/ꞵ-Catenin pathway in dermal papilla cells. This pathway is a critical signaling route for hair follicle regeneration and maintenance of the anagen phase.[9]Kwack, M.H., Kang, B.M., Kim, M.K., Kim, J.C., Sung, Y.K. (2011). Minoxidil activates ꞵ-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect. … Continue reading It also promotes the growth and specialization of hair follicle stem cells, supporting follicle growth.[10]Wang, X., Liu, Y., He, J., Wang, J., Chen, X., Yang, R. (2022). Regulation of signaling pathways in hair follicle stem cells. Burns Trauma. 10. 1-19. Available at: … Continue reading
Minoxidil stimulates the proliferation and survival of dermal papilla cells (DPCs), which are essential for hair follicle health.[11]Kang, J-I., Choi, K.Y., Han, S-C., Nam, H., Lee, G., Kang, J-H., Koh, Y.S., Hyun, J.W., Yoo, E.S., Kang, H.K. (2022). 5-Bromo-3,4-dihydroxybenzaldehyde Promotes Hair Growth through Activation of … Continue reading
It also activates the extracellular signal-regulated kinase (ERK) and protein kinase B signaling pathways, increases the ratio of anti-apoptotic to pro-apoptotic proteins (Bcl-2/Bax), and prevents cell death, thereby prolonging the anagen phase.[12]Jan, J.H., Kwon, O.S., Chung, J.H., Cho, K.H., Eun, H.C., Kim, K.H. (2004). Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. Journal of … Continue reading
Minoxidil also increases the expression of key growth factors, such as vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1), which further support follicle nourishment and angiogenesis.[13]Nagai, N., Iwai, Y., Sakamoto, A., Otake, H., Oaku, Y., Abe, A., Nagahama, T. (2019). Drug Delivery System Based on Minoxidil Nanoparticles Promotes Hair Growth in C57BL/6 Mice. International Journal … Continue reading
Minoxidil exhibits anti-inflammatory effects by modulating the production of prostaglandins and other inflammatory mediators.[14]Shin, D.W. (2022). The physiological and pharmacological roles of prostaglandins in hair growth. The Korean Journal of Physiology and Pharmacology. 26(6). 405-415. Available at: … Continue reading [15]Majewski, M., Gardas, K., Waskiel-Burnat, A., Ordak, M., Rudnicka, L. (2024). The Role of Minoxidil in Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis. Journal of Clinical … Continue reading It also inhibits collagen synthesis, which could reduce fibrosis around hair follicles, maintaining a healthy microenvironment for hair growth.[16]Fechine, C.O.C., Valente, N.Y.S., Romiti, R. (2022). Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features. Anais Brasileiros de Dermatologia. … Continue reading
Let’s break this down into the types of hair loss that minoxidil can assist with.
Oral minoxidil has been found to be as effective as 5% topical minoxidil at treating female pattern hair loss. The study found no significant difference between topical and oral minoxidil 1 mg daily in terms of efficacy for female pattern hair loss (FPHL).[17]Ramos, M.P., Sinclair, R.D., Kasprzak, M., Miot, H.A. (2020). Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss. Journal of the American Academy … Continue reading There were, however, differences in the occurrence of adverse events. While scalp itching occurred only in the topical group, only users of oral minoxidil experienced excess hair growth outside of the scalp.
Another study combined low-dose minoxidil (0.25 mg) and 25 mg spironolactone to treat FPHL.[18]Sinclair, R.D. (2018). Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. International Journal of Dermatology. 57(1). 104-109. … Continue reading The results of the study demonstrated that the combined therapy:
However, the authors didn’t report any objective measurements of hair density, either at baseline or at the end of the study period. This makes it impossible to effectively compare the results of the previously mentioned study with those of this study.
So, we can’t effectively assess the difference in efficacy of spironolactone and low-dose oral minoxidil combination therapy or oral minoxidil monotherapy. However, the authors of this study do note that they believe the combination has an added benefit for FPHL.
Of all forms of hair loss, AGA may derive the most benefit from minoxidil (whether oral or topical). This is because one of the main mechanisms of action directly addresses one of the pathological facets of AGA: reduced blood flow.
This is evidence in one study on men with AGA.[19]Lueangarun, S., Panchaprateep, R., Tempark, T., Noppakun, N. (2015). Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. Journal of the American … Continue reading In particular, it demonstrates a 100% response rate to a daily dose of 5 mg oral minoxidil. Even more impressively, subjects achieved an average 19% increase in hair count after 24 weeks.
The risk profile also appears to be favorable, with only 10% of participants reporting leg swelling. Ten percent of participants also reported a more significant side effect: an alteration in electrocardiogram (EKG) results.
These risks could theoretically be mitigated by lowering the dosage; however, one would need to consider the potential for reduced benefit. To better understand this, we’ll have to look at another study.
In line with the above results, this retrospective study showed a 90% response rate at 6-12 months for men taking 2.5-5.0 mg of oral minoxidil daily.[20]Jiminiez-Couche, J., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O.M., Fernandez-Nieto, D., Vano-Galvan, S. (2019). Effectiveness and safety of low-dose oral … Continue reading Perhaps even more impressive is the fact that 60% of these men had tried other treatments for AGA, but had previously quit due to side effects or lack of efficacy.
Figure 1: Male with AGA: Improvement with 5 mg oral minoxidil over 3 months.[21]Jiminiez-Couche, J., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O.M., Fernandez-Nieto, D., Vano-Galvan, S. (2019). Effectiveness and safety of low-dose oral … Continue reading
In line with the trend of “decreasing dosage, decreasing efficacy”, one study using 0.25 mg of oral minoxidil found a 60% response rate in male AGA patients.[22]Pirmez, R., Salas-Callo, C-I. (2020). Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. Journal of the American Academy of Dermatology. … Continue reading That’s on the low side for oral minoxidil overall, but on the high side when compared to topical minoxidil.
It’s also worth noting that there’s a key difference between this study and the one showing a 100% response rate at a 5mg daily dose. The 5mg study only included men with mild to moderate AGA; this study included both mild to moderate and severe AGA patients.
The mild to moderate group comprised 40% of study subjects, with the remaining 60% in the severe category. This suggests that low doses, such as 0.25mg, may be effective in severe AGA cases, at least in slowing and/or stopping their progression.
Figure 2: Pretreatment and post-treatment frontal region images of a 32-year-old man.[23]Pirmez, R., Salas-Callo, C-I. (2020). Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. Journal of the American Academy of Dermatology. … Continue reading
Notably, this study recorded leg swelling in only 4% of the group and found no difference in arterial pressure, suggesting that the risk of side effects reduces with decreasing dose. If these results were indeed confounded by the addition of severe AGA patients, these findings may indicate that 0.25 mg has a similar efficacy to 5 mg with a better risk profile.
All in all, it’s challenging to draw conclusions because the study designs differ significantly. In the future, it would be interesting to see how different groups with the same grade of AGA respond to 0.25 mg of minoxidil versus 5 mg of minoxidil. This could help us construct realistic treatment regimens that are both effective and minimize the risk of side effects.
Chronic telogen effluvium (CTE) is a common condition characterized by excessive hair shedding. Because one of minoxidil’s proposed mechanisms of action is its ability to shorten the “resting” telogen phase (where a lot of follicles stay in CTE, as opposed to the anagen growing phase), researchers have hypothesized that oral minoxidil may be a helpful treatment for the condition.
These hypothetical notions were explored in a recent 2017 study.[24]Perera, E., Sinclair, R. (2017). Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000 Research. 6. 1650. Available at: … Continue reading This particular study was retrospective and looked at individuals with CTE who had been prescribed oral minoxidil (dosages ranging from 0.25 mg to 2.5 mg, with the most common being 1 mg) in-clinic.
They found that most patients experienced a decrease in hair loss after 6 months, with all patients showing an improvement either at the 6 or 12-month mark. This does not make minoxidil the be-all and end-all for CTE. The oral minoxidil treatment wasn’t compared against a placebo or any other potential treatments (including combination therapies) for the condition, so we can only conclude that topical minoxidil is one potential treatment for CTE.
We also need to acknowledge that most CTE cases may have an underlying cause that, when resolved, could improve hair shedding. In these cases, addressing the root cause of CTE, whenever possible, is far more effective.
Upon investigation of topical minoxidil’s benefits for alopecia areata (AA), an autoimmune form of hair loss, researchers found that topical minoxidil, on its own, really doesn’t do much for alopecia areata (AA) patients.[25]Suchonwanit, P., Thammarucha, S., Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: … Continue reading However, interestingly, oral minoxidil at a dose of 5 mg daily appears to be effective.
Although oral minoxidil for AA hasn’t been well-studied, one study reported that 18% of AA subjects taking oral minoxidil showed an improved cosmetic response after ~35 weeks of use.
Considering the side effects of oral minoxidil are increased at a dose of 5 mg, the 18% response rate doesn’t seem too promising. But there may be one combination therapy that proves to be more effective.
Another study found that adding oral minoxidil to a current alopecia areata treatment may enhance outcomes without increasing the current dosage.
Tofacitinib is an immunomodulator drug currently used to treat alopecia areata. Although the drug is usually effective for most individuals at a 10 mg daily dosage, some users may need to double the dose to see hair growth.[26]Wambier, C.G., Craiglow, B.G., King, B.A. (2021). Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. Journal of the American Academy of Dermatology. 85(3). 743-745. … Continue reading
While this usually resolves treatment resistance, increasing the dose may also increase the risk associated with strong immunomodulatory effects, as well as the cost. So, there’s a real need for safe combination therapies to improve treatment outcomes without increasing the tofacitinib dose.
Oral minoxidil may be able to do just this. One study demonstrated that daily addition of oral minoxidil (2.5 mg for women and 5 mg, split into 2.5 mg doses, for men) to doses of tofacitinib ranging from 10 mg to 20 mg daily resulted in:
Permanent chemotherapy-induced alopecia (PCIA), a hair-shedding disorder in which hair lost to chemotherapy does not grow back 6 months after the end of chemotherapy, is considered to be generally irreversible.
One case study challenges this.[27]Yang, X., Thai, K-E. (2016). Treatment of permanent chemotherapy-induced alopecia with low-dose oral minoxidil. The Australasian Journal of Dermatology. 57(4). E120-e132. Available at: … Continue reading After one year of 1 mg daily oral minoxidil treatment, a woman with PCIA achieved considerable growth. This is pretty amazing, considering no consistently effective treatment has been found for PCIA patients, yet. While future studies are still needed to confirm these findings, these results are certainly promising.
Oral minoxidil has gained attention as an effective treatment for hair loss, but questions about its safety persist, particularly in comparison to the topical form. Here’s what the evidence shows.
There are documented cases where people taking oral minoxidil developed pericardial effusion (fluid around the heart) and even pericarditis, sometimes at low doses used for hair loss.[28]Dlova, N.C., Jacobs, T., Singh, S. (2022). Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss. JAAD Case Reports. 11(28). 94-96. Available at: … Continue reading These events are rare but have prompted caution within the medical community.
Severe cardiovascular complications like pericardial effusion have been recorded the high doses (10-40 mg) used for hypertension, with rates around 3% in these populations.[29]Bentivegna, K., Zhou, A.E., Adalsteinsson, J.A., Sloan, B. (2022). Letter in reply: Pericarditis and peripheral edema in a healthy man on low-dose oral minoxidil therapy. JAAD Case Reports. 20(29). … Continue reading However, it should be noted that this was reported in the 1980s in patients with severe hypertension, with no recent data available.
However, at the lower doses used for hair loss (0.25-5 mg), these complications are much less common and appear to be idiosyncratic (based on the individual response) rather than dose-dependent.[30]Gupta, A.K., Bamimore, M.A., Abdel-Qadir, H., Williams, G., Tosti, A., Piguet, V., Talukder, M. (2024). Low-Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event … Continue reading
Large observational studies and clinical experience with thousands of patients using low-dose oral minoxidil have not shown a significant increase in life-threatening cardiac events.[31]Vano-Galvan, S., Pirmez, R., Hermosa-Gelbard, A., Moreno-Arrones, O.M., Saceda-Corralo, D., Rodrigues-Barata, R., Jiminez-Cauhe, J., Koh, W.L., Poa, J.E., Jerjen, R., de Carvalho, L.T., John, J.M., … Continue reading Most side effects are mild and reversible with dose adjustments or discontinuation of the medication.[32]Bloch, D.L., Carlos, R.M.D. (2025). Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients. Skin Appendage Disorders. 11(1). 14-18. Available at: … Continue reading
Autopsy reports from patients who took extremely high doses (e.g., 60 mg) have not consistently shown pericardial or myocardial effusion, suggesting the risk is not universal or inevitable, even at high exposures.[33]Sobota, J.T. (1989). Review of cardiovascular findings in humans treated with minoxidil. Toxicologic pathology. 17(1 Pt 2). 193-202. Available at: https://doi.org/10.1177/019262338901700115
At high doses, minoxidil can cause changes in the heart’s electrical activity, and this has been observed in up to 60-90% of patients.[34]Hall, D., Charocopos, F., Froer, K.L., Rudolph, W. (1979). ECG changes during long-term minoxidil therapy for severe hypertension. Archives of Internal Medicine. 139(70. 790-794. Available at: PMID: … Continue reading These changes are typically subclinical, meaning they do not cause symptoms or progress to life-threatening arrhythmias, and often resolve with continued use or a reduction in the dose.
In studies of low-dose minoxidil for hair loss, only minor, asymptomatic EKG changes have been observed, with no evidence of clinically significant heart rhythm disturbances in otherwise healthy individuals.[35]Jiminiez-Cauhe, J., Pirmez, R., Muller-Ramos, P., Melo, D.F., Ortega-Quijano, D., Moreno-Arrones, O.M., Saceda-Corralo, D., Gil-Redondo, R., Hermosa-Gelbard, A., Dias-Sanabria, B., Restom, D., … Continue reading
The most common side effects at hair loss doses are hypertrichosis, mild ankle swelling, lightheadedness, and occasional palpitations.[36]Bloch, D.L., Carlos, R.M.D. (2025). Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients. Skin Appendage Disorders. 11(1). 14-18. Available at: … Continue reading Serious cardiac events are exceedingly rare. Most patients who experience side effects can continue treatment with dose adjustments. Only a small fraction discontinue due to adverse effects.
This favorable safety profile is not only a function of the lower dose but may also reflect the generally healthier status of this population compared to those prescribed high-dose minoxidil for hypertension. Most studies examining minoxidil for hair growth routinely exclude individuals with significant underlying disease.
Figure 3: Frequency of side effects using low-dose oral minoxidil according to dose.[37]Bloch, D.L., Carlos, R.M.D. (2025). Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients. Skin Appendage Disorders. 11(1). 14-18. Available at: … Continue reading
Experts recommend that patients, especially those with pre-existing heart, kidney, or liver conditions, be monitored by a healthcare provider when starting oral minoxidil.[38]Gupta, A.K., Bamimore, M.A., Haber, R., Williams, G., Piguet, V., Talukder, M. (2024). The Role of Patient- and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data from … Continue reading
Here are a number of strategies you can use to help minimize side effects while maintaining results:
Begin with the lowest effective dose and increase gradually if needed. This approach helps your body adjust and can reduce the risk of side effects, such as swelling, dizziness, or heart palpitations.
Based on the published evidence, we believe that the best balance between efficacy and safety is 2.5 mg daily for men and 0.25-1.25 mg daily for women.
Oral minoxidil has a short half-life (about 3 hours). Taking your daily dose all at once can cause higher peak blood levels, increasing the risk of side effects. Taking half in the morning and half in the evening can help keep blood levels steadier and may reduce side effects.
Taking minoxidil sublingually (letting it dissolve under your tongue) allows the drug to enter your bloodstream directly, bypassing the liver’s first-pass metabolism. Sublingual minoxidil becomes active when it reaches tissues with the right enzymes, such as those in the scalp, potentially enhancing its effectiveness. Studies suggest that sublingual minoxidil can lead to lower peak blood concentrations and fewer systemic side effects, while still promoting hair growth.[39]Guo, R-X., Zhao, Y-K., Hu, K-J., Hia, K.M., Shi, W., Yi, Y-X., Gong, H-Y., Wang, J-B., Gao, Y. (2025). Research progress in the treatment of non-scarring alopecia: mechanism and treatment. Frontiers … Continue reading
If oral minoxidil isn’t working for you because of the side effects, consider switching to the topical formulation. And, if you’re able to tolerate a 2% or 5% formulation well, you could consider adding microneedling or retinoic acid to boost your gains.
To find out more information about the potential side effects and how to avoid them, watch our video: Oral Minoxidil: How to Eliminate Side Effects.
Deciding between oral and topical minoxidil involves weighing efficacy, convenience, safety, and individual response.
At standard strengths, both 5% topical minoxidil and low-dose oral minoxidil (1-5 mg) show similar efficacy in clinical trials for total area hair count (TAHC).[40]Fazal, F., Malik, B.H., Malik, H.M., Sabir, B., Mustafa, H., Ahmed, M., Abid, A., Adil, M.L., Shafi, U., Saad, M. (2025). Can oral minoxidil be the game changer in androgenetic alopecia? A … Continue reading However, oral minoxidil often leads to slightly thicker, more robust regrowth for some users, especially those with diffuse thinning.
When topical minoxidil is combined with enhancers, such as retinoic acid, at concentrations of 7-8% (or higher), the results can surpass those seen with oral minoxidil. Our members consistently report better outcomes with these combinations, even compared to 5 mg oral minoxidil.
Underlying scalp inflammation (like seborrheic dermatitis) can reduce the effectiveness of topical minoxidil.[44]Mahe, Y.F., Cheniti, A., Tacheau, C., Antonelli, R., Planard-Luong, L., de Bernard, S., Buffat, L., Barbarat, P., Kanoun-Copy, L. (2021). Low-Level Light Therapy Downregulates Scalp Inflammatory … Continue reading Addressing inflammation is crucial before starting or modifying any hair loss treatment.
The bottom line:
Oral minoxidil is more convenient, cost-effective, and bypasses scalp enzyme limitations, making it a strong option, especially for those who don’t respond to topical or want to avoid scalp irritation.
High-strength topical minoxidil, when combined with treatments such as retinoic acid and microneedling, often delivers the best results but comes with more hassle, a higher cost, and a greater risk of scalp irritation.
Standard topical minoxidil remains a solid, accessible first-line option, especially for those who prefer to avoid systemic medications.
Ultimately, the best choice depends on your hair loss pattern, your response to treatment, your tolerance for side effects, and your lifestyle.
Yes, it is possible to use oral and topical minoxidil together; however, this approach should only be considered under the supervision of a healthcare provider. Combining both forms may provide a more robust treatment for hair loss.
Some dermatologists suggest that using both can enhance efficacy, especially for individuals who have not achieved optimal results with one form alone. However, using both simultaneously increases the risk of side effects. Therefore, the decision to combine oral and topical minoxidil should be made with professional guidance to ensure proper dosing and monitoring for adverse effects.
According to the research we just outlined, you’re a good candidate for oral minoxidil if:
On the other hand, you’re not a good candidate for oral minoxidil if…
When taking oral minoxidil for hair loss, it’s best to start with the lowest effective dose, typically 2.5 mg daily for men and 0.25–1.25 mg daily for women. The dose should be increased gradually only if needed, under the supervision of a healthcare provider. Splitting the total daily dose into morning and evening halves can help maintain steady blood levels and reduce the risk of side effects, such as palpitations, swelling, or dizziness.
Sublingual administration (allowing the tablet to dissolve under your tongue) is an alternative that may further minimize systemic side effects by bypassing the liver’s first-pass metabolism, potentially making the medication more tolerable for individuals who are sensitive to it. Throughout treatment, monitor for common side effects, such as unwanted hair growth (hypertrichosis), ankle swelling, or lightheadedness, and promptly report any serious symptoms, including chest pain or significant changes in heart rate.
Regular check-ins with your healthcare provider are essential, especially if you have underlying heart, kidney, or liver issues or take other medications that affect blood pressure. If side effects occur, consider reducing the dose, splitting it further, switching to a sublingual or topical minoxidil formulation, or discontinuing use as advised by your healthcare provider.
Avoid combining oral minoxidil with other vasodilators or muscle relaxants without consulting a healthcare professional. Address any scalp inflammation before starting or adjusting therapy to maximize results and safety.
Oral minoxidil has emerged as a compelling option for individuals seeking effective hair loss treatment, offering robust regrowth potential and convenience for both men and women who may not respond to or tolerate topical formulations. While research supports its efficacy across a range of hair loss conditions, including androgenic alopecia and chronic telogen effluvium, it is not without risks, most notably rare but serious cardiovascular side effects, as well as more common issues such as unwanted hair growth and mild edema. For many, oral minoxidil represents a powerful, evidence-based tool in the fight against hair loss, but its use should always be informed, individualized, and guided by medical expertise to ensure both safety and satisfaction. If you are a good candidate and proceed thoughtfully, oral minoxidil can play a pivotal role in your hair restoration journey.
References[+]
↑1 | Patel, P., Nessel, T.A., Kumar, D. (2023). Minoxidil. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/book/NBK482378/ Accessed: July 2025 |
---|---|
↑2 | Nestor, M.S., Ablon, G., Gade, A., Han, H., Fischer, D.L. (2021). Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. Journal of Cosmetic Dermatology. 20(12). 3759-3781. Available at: https://doi.org/10.1111/jocd.14537 |
↑3 | Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology. 39(3). 472-478. Available at: https://doi.org/10.5114/ada.2020.99947 |
↑4 | Chitalia, J., Dhurat, R., Goren, A., McCoy, J., Kovacevic, M., Situm, M., Naccarato, T., Lotti, T. (2018). Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian Subcontinent. Dermatologic Therapy. 31(6). E12688. Available at: https://doi.org/10.1111/dth.12688 |
↑5, ↑25 | Suchonwanit, P., Thammarucha, S., Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786. Available at: https://doi.org/10.2147/DDDT.S214907 |
↑6 | Beach, R.A. (2018). Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C’s of oral therapy. Dermatologic Therapy. 31(6). E12707. Available at: https://doi.org/10.1111/dth.12707 |
↑7 | Gupta, A.K., Talukder, M., Shemar, A., Priaccini, B.A., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: https://doi.org/10.115//000531890 |
↑8 | Suchonwanit, P., Thammarucha, S., Leerunyakul, K. (2019). Minoxidil and its use in hair loss disorders. Drug Design, Development and Therapy. 13. 2777-2786. Available at: https://doi.org/10.2147/DDDT.S214907 |
↑9 | Kwack, M.H., Kang, B.M., Kim, M.K., Kim, J.C., Sung, Y.K. (2011). Minoxidil activates ꞵ-catenin pathway in human dermal papilla cells: a possible explanation for its anagen prolongation effect. Journal of Dermatological Science. 62(3). 154-159. Available at: https://doi.org/10.1016/j.dermsci.2011.01.013 |
↑10 | Wang, X., Liu, Y., He, J., Wang, J., Chen, X., Yang, R. (2022). Regulation of signaling pathways in hair follicle stem cells. Burns Trauma. 10. 1-19. Available at: https://doi.org/10.1093/burnst/tkac022 |
↑11 | Kang, J-I., Choi, K.Y., Han, S-C., Nam, H., Lee, G., Kang, J-H., Koh, Y.S., Hyun, J.W., Yoo, E.S., Kang, H.K. (2022). 5-Bromo-3,4-dihydroxybenzaldehyde Promotes Hair Growth through Activation of Wnt/β-Catenin and Autophagy Pathways and Inhibition of TGF-β Pathways in Dermal Papilla Cells. Molecules. 27(7). 2176. Available at: https://doi.org/10.3390/molecules27072176 |
↑12 | Jan, J.H., Kwon, O.S., Chung, J.H., Cho, K.H., Eun, H.C., Kim, K.H. (2004). Effect of minoxidil on proliferation and apoptosis in dermal papilla cells of human hair follicle. Journal of Dermatological Science. 34(2). 91-98. Available at: https://doi.org/10.1016/j.dermsci.2004.01.002 |
↑13 | Nagai, N., Iwai, Y., Sakamoto, A., Otake, H., Oaku, Y., Abe, A., Nagahama, T. (2019). Drug Delivery System Based on Minoxidil Nanoparticles Promotes Hair Growth in C57BL/6 Mice. International Journal of Nanomedicine. 1(14). 7921-7931. Available at: https://doi.org/10.2147/IJN.S225496 |
↑14 | Shin, D.W. (2022). The physiological and pharmacological roles of prostaglandins in hair growth. The Korean Journal of Physiology and Pharmacology. 26(6). 405-415. Available at: https://doi.org/10.4196/kjpp.2022.26.6.405 |
↑15 | Majewski, M., Gardas, K., Waskiel-Burnat, A., Ordak, M., Rudnicka, L. (2024). The Role of Minoxidil in Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 13(24). 7712. Available at: https://doi.org/10.3390/jcm13247712 |
↑16 | Fechine, C.O.C., Valente, N.Y.S., Romiti, R. (2022). Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features. Anais Brasileiros de Dermatologia. 97(3). 348-357. Available at: https://doi.org/10.1016/j.abd.2021.08.008 |
↑17 | Ramos, M.P., Sinclair, R.D., Kasprzak, M., Miot, H.A. (2020). Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss. Journal of the American Academy of Dermatology. 82(1). 252-253. Available at: https://doi.org/10.1016/j.jaad.2019.08.060 |
↑18 | Sinclair, R.D. (2018). Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. International Journal of Dermatology. 57(1). 104-109. Available at: https://doi.org/10.1111/ijd.13838 |
↑19 | Lueangarun, S., Panchaprateep, R., Tempark, T., Noppakun, N. (2015). Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. Journal of the American Academy of Dermatology. 72(5). AB113. Available at: https://doi.org/10.1016/j.jaad.2015.02.466 |
↑20, ↑21 | Jiminiez-Couche, J., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O.M., Fernandez-Nieto, D., Vano-Galvan, S. (2019). Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. 81(2). 648-649. Available at: https://doi.org/10.1016/j.jaad.2019.04.054 |
↑22, ↑23 | Pirmez, R., Salas-Callo, C-I. (2020). Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. Journal of the American Academy of Dermatology. 82(1). E21-e22. Available at: https://doi.org/10.1016/j.jaad.2019.08.084 |
↑24 | Perera, E., Sinclair, R. (2017). Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000 Research. 6. 1650. Available at: https://doi.org/10.12688/f1000research.11775.1 |
↑26 | Wambier, C.G., Craiglow, B.G., King, B.A. (2021). Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. Journal of the American Academy of Dermatology. 85(3). 743-745. Available at: https://doi.org/10.1016/j.jaad.2019.08.080 |
↑27 | Yang, X., Thai, K-E. (2016). Treatment of permanent chemotherapy-induced alopecia with low-dose oral minoxidil. The Australasian Journal of Dermatology. 57(4). E120-e132. Available at: https://doi.org/10.1111/ajd.12350 |
↑28 | Dlova, N.C., Jacobs, T., Singh, S. (2022). Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss. JAAD Case Reports. 11(28). 94-96. Available at: https://doi.org/10.1016/j.jdcr.2022.07.044 |
↑29 | Bentivegna, K., Zhou, A.E., Adalsteinsson, J.A., Sloan, B. (2022). Letter in reply: Pericarditis and peripheral edema in a healthy man on low-dose oral minoxidil therapy. JAAD Case Reports. 20(29). 110-111. Available at: https://doi.org/10.1016/j.jdcr.2022.08.057 |
↑30 | Gupta, A.K., Bamimore, M.A., Abdel-Qadir, H., Williams, G., Tosti, A., Piguet, V., Talukder, M. (2024). Low-Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions. Journal of Cosmetic Dermatology. 24(1). E16574. Available at: https://doi.org/10.1111/jocd.16574 |
↑31 | Vano-Galvan, S., Pirmez, R., Hermosa-Gelbard, A., Moreno-Arrones, O.M., Saceda-Corralo, D., Rodrigues-Barata, R., Jiminez-Cauhe, J., Koh, W.L., Poa, J.E., Jerjen, R., de Carvalho, L.T., John, J.M., Salas-Callo, C.I., Vincenzi, C., Yin, L., Lo-Sicco, K., Piraccini, B.M., Rudnicka, L., Shapiro, J., Tosti, A., Sinclair, R., Bhoyrul, B. (2021). Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology. 84(6). 1644-1651. Available at: https://doi.org/10.1016/j.jaad.2021.02.054 |
↑32, ↑36, ↑37 | Bloch, D.L., Carlos, R.M.D. (2025). Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients. Skin Appendage Disorders. 11(1). 14-18. Available at: https://doi.org/10.1159/000539969 |
↑33 | Sobota, J.T. (1989). Review of cardiovascular findings in humans treated with minoxidil. Toxicologic pathology. 17(1 Pt 2). 193-202. Available at: https://doi.org/10.1177/019262338901700115 |
↑34 | Hall, D., Charocopos, F., Froer, K.L., Rudolph, W. (1979). ECG changes during long-term minoxidil therapy for severe hypertension. Archives of Internal Medicine. 139(70. 790-794. Available at: PMID: 36861 |
↑35 | Jiminiez-Cauhe, J., Pirmez, R., Muller-Ramos, P., Melo, D.F., Ortega-Quijano, D., Moreno-Arrones, O.M., Saceda-Corralo, D., Gil-Redondo, R., Hermosa-Gelbard, A., Dias-Sanabria, B., Restom, D., Porrino-Bustamante, M.L., Pindado-Ortega, C., Berna-Rico, E., Fernandez-Nieto, D., Ramos, M., Jaen-Olasolo, P., Vano-Galvan, S. (2024). Safety of Low-Dosr Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermo-Sifiliograficas. 115(1). 28-35. Available at: https://doi.org/10.1016/j.ad.2023.07.019 |
↑38 | Gupta, A.K., Bamimore, M.A., Haber, R., Williams, G., Piguet, V., Talukder, M. (2024). The Role of Patient- and Drug-Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data from the United States Food and Drug Administration Adverse Event Reporting System. Journal of Cosmetic Dermatology. 24(2). E16732. Available at: https://doi.org/10.1111/jocd.16732 |
↑39 | Guo, R-X., Zhao, Y-K., Hu, K-J., Hia, K.M., Shi, W., Yi, Y-X., Gong, H-Y., Wang, J-B., Gao, Y. (2025). Research progress in the treatment of non-scarring alopecia: mechanism and treatment. Frontiers in Pharmacology. 26(1544068). Available at: https://doi.org/10.3389/fphar.2025.1544068 |
↑40 | Fazal, F., Malik, B.H., Malik, H.M., Sabir, B., Mustafa, H., Ahmed, M., Abid, A., Adil, M.L., Shafi, U., Saad, M. (2025). Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review and meta-analysis comparing topical and oral minoxidil for treating androgenetic alopecia. Skin Health and Disease. 5(2). 95-101. Available at: https://doi.org/10.1093/skinhd/vzaf009 |
↑41 | Goren, A., Shapiro, J., Roberts, J., McCoy, J., Desai, N., Zarrab, X., Pietrzak, A., Lotti, T. (2014). Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatologic Therapy. Available at: https://doi.org/10.1111/dth.12164 |
↑42 | Pirmez, R., Salas-Callo, C-I. (2020). Very-low-dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation. Journal of the American Academy of Dermatology. 82(1). E21-e22. Available at: https://doi.org/10.1016/j.jaad.2019.08.084 |
↑43 | Shadi, Z. (2023). Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatological Therapy (Heidelb). 13(5). 1157-1169. Available at: https://doi.org/10.1007/s13555-023-00919-x |
↑44 | Mahe, Y.F., Cheniti, A., Tacheau, C., Antonelli, R., Planard-Luong, L., de Bernard, S., Buffat, L., Barbarat, P., Kanoun-Copy, L. (2021). Low-Level Light Therapy Downregulates Scalp Inflammatory Biomarkers in Men with Androgenetic Alopecia and Boost Minoxidil 2% to Bring a Sustainable Hair Regrowth Activity. Lasers in Surgery & Medicine. 53(9). Available at: https://doi.org/10.1002/lsm.23398 |
Get personalized support, product recommendations, video calls, and more from our researchers, trichologists, and PhD's dedicated to getting you the best possible outcomes.
Learn MoreDr. Sarah King is a researcher & writer who holds a BSc in Medical Biology, an MSc in Forensic Biology, and a Ph.D. in Molecular and Cellular Biology. While at university, Dr. King’s research focused on cellular aging and senescence through NAD-dependent signaling – along with research into prostaglandins and their role in hair loss. She is a co-author on several upcoming manuscripts with the Perfect Hair Health team.
Get personalized support, product recommendations, video calls, and more from our researchers, trichologists, and PhD's dedicated to getting you the best possible outcomes.
Join Now